Contact
Please use this form to send email to PR contact of this press release:
Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin
TO:
Please use this form to send email to PR contact of this press release:
Achaogen Reaches 50 Percent Patient Enrollment in Phase 3 EPIC Registration Trial of Plazomicin
TO: